Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
May 07 2024 - 7:00AM
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that
is reimagining therapeutic delivery, today announced it will report
financial results and provide a corporate update for the first
quarter ended March 31, 2024. The company’s management will host a
webcast and conference call on Wednesday, May 15, 2024, after the
close of financial markets.
Conference Call and Webcast Information
Date: |
|
Wednesday, May 15, 2024 |
|
|
|
Time: |
|
4:30 PM Eastern time / 1:30 PM
Pacific time |
|
|
|
Conference
Call: |
|
Domestic 1-877-423-9813 |
|
|
International 1-201-689-8573 |
|
|
Conference ID 13746163 |
|
|
Call me for instant telephone
access |
|
|
|
Live
Webcast: |
|
https://investors.bioratherapeutics.com/events-presentations |
|
|
|
A replay will be available online for 60 days following the call
via the Investor Relations section of the company website.
About Biora TherapeuticsBiora Therapeutics is
reimagining therapeutic delivery. By creating innovative smart
pills designed for targeted drug delivery to the GI tract, and
systemic, needle-free delivery of biotherapeutics, the company is
developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics platforms:
the NaviCap™ targeted oral delivery platform, which is designed to
improve outcomes for patients with inflammatory bowel disease
through treatment at the site of disease in the gastrointestinal
tract, and the BioJet™ systemic oral delivery platform, which is
designed to replace injection for better management of chronic
diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development, preclinical
and clinical trial activities, and partnering and collaboration
efforts with third parties, are forward-looking statements. In some
cases, you can identify forward-looking statements by terms such as
“may,” “might,” “will,” “objective,” “intend,” “should,” “could,”
“can,” “would,” “expect,” “forward,” “believe,” “design,”
“estimate,” “predict,” “potential,” “plan,” “target,” or the
negative of these terms, and similar expressions intended to
identify forward-looking statements. These statements reflect our
plans, estimates, and expectations, as of the date of this press
release. These statements involve known and unknown risks,
uncertainties and other factors that could cause our actual results
to differ materially from the forward-looking statements expressed
or implied in this press release. Such risks, uncertainties, and
other factors include, among others, our ability to innovate in the
field of therapeutics, our ability to make future filings and
initiate and execute clinical trials on expected timelines or at
all, our ability to obtain and maintain regulatory approval or
clearance of our products on expected timelines or at all, our
plans to research, develop, and commercialize new products, the
unpredictable relationship between preclinical study results and
clinical study results, our expectations regarding allowed patents
or intended grants to result in issued or granted patents, our
expectations regarding opportunities with current or future
pharmaceutical collaborators or partners, our ability to raise
sufficient capital to achieve our business objectives, and those
risks described in “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in our
Annual Report on Form 10-K for the year ended December 31, 2023
filed with the SEC and other subsequent documents, including
Quarterly Reports, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law. Investor ContactChuck
PadalaManaging Director, LifeSci
AdvisorsIR@bioratherapeutics.com(646) 627-8390
Media
Contactmedia@bioratherapeutics.com
Biora Therapeutics (NASDAQ:BIOR)
Historical Stock Chart
From May 2024 to Jun 2024
Biora Therapeutics (NASDAQ:BIOR)
Historical Stock Chart
From Jun 2023 to Jun 2024